GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Shares of GlaxoSmithKline were down 0.2% in trading on Thursday after the drug maker said its experimental monoclonal antibody treatment did not meet the primary endpoint in a mid-stage trial evaluating its use in hospitalized COVID-19 patients of all age groups. As part of the study's design, the therapy, otilimab, was given in addition to the standard of care, which includes treatments such as Gilead Sciences Inc.'s antiviral Veklury.

GSK to refocus study of experimental COVID-19 antibody treatment on patients 70 and older

GlaxoSmithKline PLC (LON:GSK) said it is tweaking clinical studies on a COVID-19 treatment candidate after missing the primary goal. Otilimab, a monoclonal antibody, did not make a significant difference when used to treat patients in addition to standard of care, compared to those receiving standard of care alone.

GlaxoSmithKline tweaks COVID-19 treatment study after missing primary goal

Sanofi

Sanofi and GlaxoSmithKline PLC (LON:GSK) have announced details of a phase II study for their collaborative coronavirus vaccine. Britain's Glaxo and France's Sanofi are the world's two largest vaccine companies but have been left floundering in their attempts to come up with a product by rivals Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna.

GlaxoSmithKline and Sanofi to push ahead with phase II trial of Covid-19 vaccine

The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an "insufficient" immune response to the virus in people older than 50 years.

Sanofi, GlaxoSmithKline start new COVID-19 vaccine study after failed trial

Sanofi SA (NASDAQ: SNY)and GlaxoSmithKline Plc (NYSE: GSK) have initiated a new Phase 2 study with 720 volunteers aged 18 and finalize the antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. The companies have corrected the shot's formulation, which was weaker and failed to create enough immune response in people 50 years and older.

Sanofi/GlaxoSmithKline Initiate COVID-19 Vaccine Development After Setback

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

FirstService

Masco

VictoryShares Nasdaq Next 50 ETF

Rollins

S&P Global

T. Rowe Price Group

Tractor Supply

Victory Capital Holdings

When it comes to investing in dividend stocks, companies that significantly increase their payouts are more attractive than those with higher yields. The post 10 Dividend Stocks Increasing Their Payouts  appeared first on InvestorPlace.

10 Dividend Stocks Increasing Their Payouts

Vir Biotechnology

Glaxo (GSK)/Vir Biotech expands their existing coronavirus collaboration for developing new monoclonal antibody candidates for influenza and other respiratory viruses.

Glaxo (GSK)/Vir Biotech to Develop Antibodies for Influenza

The biotech will get $345 million through an upfront payment and equity investment.

Vir Biotechnology and GlaxoSmithKline Expand Their Partnership

Shares of Vir Biotechnology Inc. were up 12.8% in premarket trading on Wednesday after the company said it would expand its research agreement with GlaxoSmithKline to include the flu and other respiratory diseases. As part of the deal, GSK will pay Vir $225 million upfront and will make an equity investment of $120 million in the biotech; it also has the option to develop one drug for $300 million, with the possibility of an additional $200 million in milestone payments.

Vir, GSK ink new R&D deal

GSK is one of the few discounted pharma stocks which also provides an ample dividend. Unfortunately, recent announcements have signaled to the markets that the dividend will probably be reduced in order to charge growth projects.

GlaxoSmithKline: Distribution Change Signals A Future Of Acquisitions

Novartis

Basel, February 11, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire GSK's cephalosporin antibiotics business, reinforcing its leading global position in antibiotics.

Sandoz announces agreement to acquire GSK's cephalosporin antibiotics business, reinforcing its leading global position in antibiotics

Eli Lilly

Moderna

Sorrento Therapeutics Inc

These biotech companies may be among the winners of the coronavirus treatment race -- if all goes well in clinical trials.

How Risky Are These Heavily Shorted COVID Stocks?

The approval of Glaxo's (GSK) Rukobia is based on data from the pivotal phase III BRIGHTE study. Rukobia was approved in the United States in July last year.

Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV

GSK's yield has been 5-6% lately, which for a quality pharma is attractive. That, and no rise for many years, suggests it may be not be supported.

GlaxoSmithKline: Don't Rely On Dividend Maintenance At The Current Level

Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.

Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track

GlaxoSmithKline (GSK) CEO, Emma Walmsley on Q4 2020 Results - Earnings Call Transcript

U.S.-based shares of GlaxoSmithKline PLC (NYSE:GSK)(LSE:GSK) sank over 5% in morning trading on Wednesday on the back of reporting fourth-quarter 2020 earnings results that missed consensus estimates.

GlaxoSmithKline Slips on 4th-Quarter Earnings Miss

GlaxoSmithKline Plc (NYSE: GSK) expects profit to fall this year, as the company cites an increase in research spending in pursuit of the next blockbusters.

GlaxoSmithKline Shares Slip On Weaker Profit Forecast For 2021, Plans To Cut Dividend

Glaxo miss earnings estimates in the fourth quarter of 2020 but beats the same for revenues. Stock down.

Glaxo (GSK) Miss Earnings Estimates in Q4, Revenues Beat

Shares of GlaxoSmithKline (NYSE:GSK) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share decreased 6.06% year over year to $0.31, which missed the estimate of $0.64.

Recap: GlaxoSmithKline Q4 Earnings

Britain's GSK said on Wednesday its plan to split into two businesses was on track, as the drugmaker aiding in COVID-19 vaccine developments forecast 2021 profit to fall by a mid- to high-single digit percentage.

GSK says split plans on track, forecasts dip in profit this year

CureVac B.V

UK pharma giant GlaxoSmithKline (GSK) and German biotech CureVac plan to co-develop "next generation" vaccines that could work against multiple coronavirus variants at once, the companies announced Wednesday. The vaccines could be available in 2022, subject to authorization, and could work as a booster if immunity from another vaccine wanes, or for people who haven't yet been immunized, the companies said.

GSK and CureVac are making 'next-generation' vaccines that they say can tackle multiple COVID-19 variants at once

U.K.-based GlaxoSmithKline Plc (NYSE: GSK) and Germany's CureVac BV (NASDAQ: CVAC) have announced to work together in a €150 million collaboration for the development of a new generation of COVID-19 vaccines to tackle emerging variants of the virus.

GlaxoSmithKline, CureVac In Pact To Develop Vaccines For COVID-19 Variants

GSK and CureVac said their approach could potentially tackle multiple coronavirus strains in one vaccine shot

News for GlaxoSmithKline Stock (GSK)